Displaying 3661 - 3680 of 4409
0606011 Informal Interpretation
FTC Staff: Alpena, Michigan, Public Schools Planned Pharmaceutical Transfer Falls Within NPIA; Final Consent Orders Approved in Matters of Nations Title and Basic Research Consumer Protection Matters
Time Warner, Inc.; Turner Broadcasting System, Inc.; Tele-Communications, Inc.; and Liberty Media Corporation
Final consent order requiring the restructuring of the acquisition of Turner Broadcasting System, Inc. settles antitrust concerns that the acquisition would restrict competition in cable television programming and distribution. The order requires Tele-Communications, Inc., the nation's number one cable operator, to divest its interests in Turner; reduces contractual agreements between TCI, Turner and Time Warner to carry certain programming; reduces opportunities for bundling programming; prohibits price discrimination against competing cable systems; and requires Time Warner's cable systems to carry a rival news channel to compete with CNN.
FTC Testifies on Broadband Internet Access Services
Johnson & Johnson, In the Matter of
The consent order protects competition in three medical device product markets affected by Johnson & Johnson’s proposed $25.4 billion acquisition of Guidant Corporation. Under the terms of the order, J&J is required to 1) grant to a third party a 6 fully paid-up, non-exclusive, irrevocable license, enabling that third party to make and sell drug eluting stents with the Rapid Exchange delivery system, 2) divest to a third party J&J’s endoscopic vessel harvesting product line, and 3) end its agreement to distribute Novare Surgical System, Inc.’s proximal anastomotic assist device. On May 31st, 2006 the Commission granted a petition filed by Johnson and Johnson Corporation, requesting that the FTC reopen and set aside the entire decision and order concerning the proposed acquisition of Guidant Corporation.
Prepared Statement of the Federal Trade Commission On Investigation of Gasoline Price Manipulation and Post-Katrina Gasoline Price Increases
FTC Provides Senate Testimony on its Investigation of Gasoline Price Manipulation and Post-Katrina Gasoline Price Increases
FTC Releases Report on its Investigation of Gasoline Price Manipulation and Post-Katrina Gasoline Price Increases
Commission Approves Divestiture in Matter of DaVita/Gambro; FTC Approves Petition for Sale of Meow Mix Company to Del Monte Corporation; Final Consent Order Approved in Matter of Dynamic Health of Florida
DaVita, Inc.
Nestle Holdings, Inc., and Ralston Purina Company
Nestle settled antitrust charges that its $10.3 billion proposed acquisition of Ralston Purina Company would substantially lessen competition in the United States market for dry cat food through the elimination of direct competition between the two firms and increase the likelihood that the combined firm could unilaterally exercise market power. The order requires the divestiture of Ralston's Meow Mix and Alley Cat brands to J.W. Childs Equity Partners II,L.P.
Valassis Communications, Inc., In the Matter of
Valassis, a leading producer of free-standing newspaper inserts in the United States, has settled charges that it violated Section 5 of the FTC Act by attempting to collude with News America Marketing, its only rival, to eliminate competition between the two companies. During a conference call with industry analysts, a Valassis executive invited NewsAmerica to join in a scheme to allocate customers and fix prices in order to end an ongoing price war between the two companies. Under the consent order settling the FTC’s complaint, Valassis is barred from engaging in or inviting collusive agreements with other publishers or attempting to collude with its competitors.
Procter & Gamble Company and The Gillette Company, In the Matter of
Bureau of Competition Issues FY 2005 Summary of Pharmaceutical Company Settlement Agreements
Allergan, Inc., and Inamed Corporation, In the Matter of
The consent order requires that Allergan and Inamed divest the rights to develop and distribute Reloxin, a potential Botox rival, to settle charges that Allergan’s $3.2 billion purchase of Inamed would reduce competition and force consumers to pay higher prices for botulinum toxin type A products. Under the terms of the FTC settlement, the companies will return the development and distribution rights to Reloxin to Ipsen Ltd., its U.K.- based manufacturer.
Commission Approves Final Consent Order in Matter of Allergan/Inamed
Maintaining Competition, FTC Allows Fresenius $3.5 Billion Deal to Buy Rival Dialysis Provider Renal Care Group
Displaying 3661 - 3680 of 4409